This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Valeant Pharmaceuticals International, Inc.

Drug Names(s): timolol maleate

Description: Istalol is a non-selective beta-blocker that is applied to the surface of the eye once a day. It significantly reduces the amount of fluid that is produced by the ciliary body.

Deal Structure: Bausch + Lomb and ISTA
In March 2012, Bausch + Lomb and ISTA Pharmaceuticals announced that they have signed a definitive agreement under which Bausch + Lomb will acquire ISTA. This acquisition closed in June 2012.

Bausch + Lomb and Valeant
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.

In August 2013, Valeant announced it has completed the acquisition of Bausch + Lomb.

Partners: Senju Pharmaceutical Co., Ltd.

Istalol News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug